Geron Corp. (GERN)
1.57
+0.06
(+3.97%)
USD |
NASDAQ |
Sep 04, 16:00
1.57
0.00 (0.00%)
After-Hours: 20:00
Geron Research and Development Expense (Quarterly) : 22.03M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 22.03M |
| March 31, 2026 | 14.96M |
| December 31, 2025 | 15.83M |
| September 30, 2025 | 21.07M |
| June 30, 2025 | 21.74M |
| March 31, 2025 | 15.08M |
| December 31, 2024 | 23.43M |
| September 30, 2024 | 20.15M |
| June 30, 2024 | 30.78M |
| March 31, 2024 | 29.37M |
| December 31, 2023 | 32.91M |
| September 30, 2023 | 29.43M |
| June 30, 2023 | 35.49M |
| March 31, 2023 | 27.22M |
| December 31, 2022 | 28.21M |
| September 30, 2022 | 24.60M |
| June 30, 2022 | 20.61M |
| March 31, 2022 | 22.10M |
| December 31, 2021 | 24.15M |
| September 30, 2021 | 18.53M |
| June 30, 2021 | 21.94M |
| March 31, 2021 | 21.11M |
| December 31, 2020 | 16.23M |
| September 30, 2020 | 13.61M |
| June 30, 2020 | 10.84M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.80M |
| December 31, 2019 | 24.92M |
| September 30, 2019 | 11.11M |
| June 30, 2019 | 10.13M |
| March 31, 2019 | 5.906M |
| December 31, 2018 | 5.081M |
| September 30, 2018 | 2.707M |
| June 30, 2018 | 3.204M |
| March 31, 2018 | 2.44M |
| December 31, 2017 | 2.523M |
| September 30, 2017 | 2.637M |
| June 30, 2017 | 2.499M |
| March 31, 2017 | 3.374M |
| December 31, 2016 | 4.12M |
| September 30, 2016 | 4.319M |
| June 30, 2016 | 4.575M |
| March 31, 2016 | 5.033M |
| December 31, 2015 | 3.982M |
| September 30, 2015 | 4.05M |
| June 30, 2015 | 4.812M |
| March 31, 2015 | 4.987M |
| December 31, 2014 | 4.351M |
| September 30, 2014 | 5.994M |
| June 30, 2014 | 5.151M |
| March 31, 2014 | 5.211M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Precigen, Inc. | 6.963M |
| Editas Medicine, Inc. | 19.76M |
| Agenus, Inc. | 14.76M |
| Amgen, Inc. | 1.868B |
| Anika Therapeutics, Inc. | 7.341M |